Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

TRENDING TOPICS:

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Nov 15 2017

Full Issue

In Anticipated Study, Monthly Opioid Treatment Shown To Be About As Effective As Daily Pill

But the monthly treatment is more difficult because participants have to wean themselves off opioids for a period of three days before they could start taking Vivitrol. Because of that hurdle, patients failed to start on Vivitrol at four times the rate that they did on the daily medication Suboxone.

The New York Times: Study Finds Competing Opioid Treatments Have Similar Outcomes

A long-awaited study has found that two of the main medications for treating opioid addiction are similarly effective, a finding likely to intensify the hard-fought competition between drugmakers seeking to dominate the rapidly expanding opioid treatment market. The study, funded by the federal government, compared Vivitrol, which comes in a monthly shot and blocks the effects of opioids, and Suboxone, which is taken daily in strips that dissolve on the tongue and contains a relatively mild opioid that helps minimize withdrawal symptoms and cravings. (Goodnough and Zernike, 11/14)

The Washington Post: Medications To Kick Opioid Addiction Are Equally Effective, Study Finds

The first major head-to-head comparison of medically assisted treatment approaches confirms that users now have two research-based options, according to the team of scientists led by Joshua D. Lee and John Rotrosen of New York University Medical School. But each method also showed a distinct disadvantage. (Bernstein, 11/14)

The Wall Street Journal: Opioid Addiction Study Finds The Drug Vivitrol, Once Begun, Is As Effective As Suboxone

“What is new, and what the study was really about from our perspective, was: What happens if you are able to get people onto one or the other medication?” said his colleague, John Rotrosen, another leader of the study and a physician and psychiatry professor at New York University School of Medicine. “What we were really hoping, and what we found was...the two medications would be sufficiently equal, so providers and patients and families really recognized they have a choice,” he said. (Whalen, 11/14)

Stat: Long-Awaited Study Finds Monthly Vivitrol As Effective As Daily Pill For Opioid Addiction

Previously, there’s been a “widespread belief” that patients “don’t do as well on naltrexone as they do on buprenorphine,” said Dr. Nora Volkow, director of NIDA. “We’re hopeful this changes the prejudice.” (Blau, 11/14)

In other news on the opioid crisis —

The Washington Post: 44 State Attorneys General Want Repeal Of Law That Curbed DEA Powers

Forty-four state attorneys general asked Congress on Tuesday to repeal a law that effectively strips the Drug Enforcement Administration of potent weapons against large drug companies that have allowed hundreds of millions of pain pills to spill onto the black market. The state law enforcement officials, many from places hit hard by the opioid epidemic, signed a letter from the National Association of Attorneys General to Republican and Democratic leaders in the House and Senate. Congress approved the law by unanimous consent, without a vote in either chamber, in 2016. (Bernstein and Higham, 11/14)

Boston Globe: Mass. Governor Aims To Expand Battle Against Opioid Addiction

Governor Charlie Baker proposed Tuesday a sweeping package intended to boost the state’s battle against opioid addiction, including an effort to ensure higher-quality addiction treatment and a new provision allowing doctors to commit unwilling patients to 72 hours in a treatment facility. Noting that the state has added 1,100 treatment beds since 2015, Baker said it is now time to address some of the gaps, particularly in the care provided after detoxification. (Freyer, 11/15)

Columbus Dispatch: DeWine Urging Congress To Restore DEA’s Power To Fight Opioid Epidemic

Ohio Attorney General Mike DeWine joined 43 other state attorneys general to ask Congress to repeal a law they argue has damaged the Drug Enforcement Agency’s ability to crack down on drug manufacturers and distributors that have contributed to the nation’s sweeping opioid epidemic. In a letter Tuesday to House and Senate leadership, the attorneys general argue that a bill passed by voice vote in 2016 made it more difficult for the DEA to take action against drug companies that were flooding communities with prescription painkillers. (Wehrman, 11/14)

The Nashville Tennessean: A Personal Quest To Give Doctors The Tools To Battle Opioid Abuse

A Memphis doctor who knows first-hand the pain of losing a child to an overdose is fighting to change medical education in Tennessee so there are more physicians throughout the state with addiction medicine expertise. (Fletcher, 11/14)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF